# A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

> **NCT04349969** · PHASE1 · COMPLETED · sponsor: **Akesobio Australia Pty Ltd** · enrollment: 38 (actual)

## Conditions studied

- Neoplasms Malignant

## Interventions

- **DRUG:** AK117
- **DRUG:** AK117+AK104

## Key facts

- **NCT ID:** NCT04349969
- **Lead sponsor:** Akesobio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04349969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04349969, "A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04349969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*